ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비주사형 인슐린 시장 규모는 최근 몇 년간 크게 성장했습니다. 2025년 21억 4,000만 달러에서 2026년에는 23억 5,000만 달러에 이르고, CAGR 9.9%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 당뇨병 환자 증가, 비주사 요법에 대한 환자 선호도 증가, 인슐린 제제의 발전, 정부의 당뇨병 치료 촉진 정책, 당뇨병 합병증에 대한 인식 개선 등이 주요 요인으로 작용한 것으로 분석됩니다.
비주사형 인슐린 시장 규모는 향후 몇 년간 견고성장이 전망됩니다. 2030년에는 34억 1,000만 달러에 이르고, CAGR은 9.8%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 경구 및 흡입형 인슐린의 기술 발전, 디지털 헬스 솔루션의 통합, 고령 인구 증가, 신흥 시장에서의 의료 인프라 확충, 당뇨병에 대한 개인 맞춤형 의료 접근법 등이 있습니다. 예측 기간의 주요 동향으로는 경구용 인슐린 전달 시스템, 폐용 인슐린 흡입기, 환자 중심의 당뇨병 관리, 비침습적 모니터링 및 투여, 생물학적 이용률 향상을 위한 제제 혁신 등이 있습니다.
비만과 당뇨병의 유병률 증가는 향후 몇 년 동안 비주사형 인슐린 시장의 성장을 견인할 것으로 예측됩니다. 비만은 과도한 체지방 축적을 특징으로 하는 상태이며, 보통 칼로리 섭취와 에너지 소비의 불균형으로 인해 발생합니다. 한편, 당뇨병(일반적으로 당뇨병으로 알려져 있음)은 지속적인 고혈당을 특징으로 하는 대사 장애 그룹을 말합니다. 비주사형 인슐린은 치료 순응도 향상, 체중 조절에 대한 잠재적 이점, 기존 인슐린 요법에 대한 편리한 대안을 제공함으로써 당뇨병 및 비만 관리에 활용되고 있습니다. 예를 들어, 2023년 6월 미국 공중보건 연구기관인 건강지표평가연구소(IHME)가 발표한 보고서에 따르면, 전 세계적으로 5억 명 이상이 당뇨병을 앓고 있으며, 2050년까지 13억 명을 넘어설 것으로 예측했습니다. 따라서 비만과 당뇨병 유병률 증가는 비주사형 인슐린 시장의 성장을 견인하고 있습니다.
비주사형 인슐린 시장에서 활동하는 주요 기업들은 여러 번의 인슐린 주사에 의존하는 환자들의 일상적인 당뇨병 관리를 개선하기 위해 바늘이 필요 없는 경구용 인슐린 스프레이와 같은 약물 전달 기술 혁신에 집중하고 있습니다. 바늘이 필요 없는 인슐린 스프레이는 혈당 조절을 위한 통증 없는 편리한 대안을 제공하며, 복용량을 입안에 직접 분무할 수 있습니다. 예를 들어, 2023년 11월 인도에 본사를 둔 기술 플랫폼 기업 니들프리 테크놀로지스(Needle Free Technologies)는 당뇨병 환자, 특히 기존 주사형 인슐린 사용에 어려움을 겪고 있는 환자들에게 보다 사용하기 쉬운 솔루션을 제공하기 위해 경구용 인슐린 스프레이 '오즐린'을 출시했습니다. 스프레이 '오즐린'을 발표했습니다. 오즐린이 승인되면 인슐린 투여를 위한 보다 편리하고 통증 없는 대안을 제공함으로써 당뇨병 치료에 변화를 가져올 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Non-injectable insulin is a form of insulin that can be administered without the use of injections. These non-injectable options are designed to provide alternatives to traditional insulin injections, making diabetes management more convenient and potentially enhancing the overall quality of life for individuals with diabetes.
The main types of non-injectable insulin are synthetic insulin and semi-synthetic insulin. Synthetic insulin is artificially produced using biotechnological methods rather than being derived from animal sources. It is available in various forms, including pills, sprays, and other products, and is distributed through hospital pharmacies, online pharmacies, and drug stores.
Tariffs have impacted the non-injectable insulin market by increasing the cost of imported raw materials, medical devices, and advanced formulation technologies. This has particularly affected segments such as oral pills and pulmonary inhalers, with Asia-Pacific regions like China and India facing higher import duties due to their reliance on international manufacturing. While tariffs have raised production costs and slowed market adoption in some regions, they have also incentivized local manufacturing and innovation, pushing companies to develop cost-effective and locally produced non-injectable insulin solutions.
The non-injectable insulin market research report is one of a series of new reports from The Business Research Company that provides non-injectable insulin market statistics, including non-injectable insulin industry global market size, regional shares, competitors with a non-injectable insulin market share, detailed non-injectable insulin market segments, market trends and opportunities, and any further data you may need to thrive in the non-injectable insulin industry. This non-injectable insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-injectable insulin market size has grown strongly in recent years. It will grow from $2.14 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing prevalence of diabetes, rising patient preference for non-injective therapies, advancements in insulin formulation, government initiatives promoting diabetes care, growing awareness about diabetes complications.
The non-injectable insulin market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to technological advancements in oral and inhalable insulin, integration of digital health solutions, rising geriatric population, expansion of healthcare infrastructure in emerging markets, personalized medicine approaches for diabetes. Major trends in the forecast period include oral insulin delivery systems, pulmonary insulin inhalers, patient-centric diabetes management, non-invasive monitoring & dosing, formulation innovations for improved bioavailability.
The rising prevalence of obesity and diabetes is expected to drive the growth of the non-injectable insulin market in the coming years. Obesity is a condition marked by excessive body fat accumulation, typically resulting from an imbalance between calorie intake and energy expenditure, while diabetes mellitus, commonly known as diabetes, encompasses a group of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin is used to manage diabetes and obesity by improving treatment adherence, offering potential benefits for weight management, and providing a more convenient alternative to traditional insulin therapy. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over 500 million people globally were living with diabetes, and this number is projected to exceed 1.3 billion by 2050. Therefore, the rising prevalence of obesity and diabetes is driving the growth of the non-injectable insulin market.
Major companies operating in the non-injectable insulin market are concentrating on innovations in drug delivery technologies, such as needle-free oral insulin sprays, to enhance the daily management of diabetes for patients who rely on multiple insulin injections. A needle-free insulin spray provides a painless and convenient alternative for regulating blood glucose, allowing doses to be administered directly into the mouth. For instance, in November 2023, NiedlFree Technologies, an India-based technology platform, launched Ozulin, an oral insulin spray designed to offer a more user-friendly solution for individuals with diabetes, particularly those who struggle with traditional injectable insulin. If approved, Ozulin could transform diabetes care by providing a more convenient and pain-free option for insulin administration.
In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed sum. This acquisition combines Abbott's expertise in continuous glucose monitoring with Bigfoot's smart insulin management systems, strengthening Abbott's position as a leader in comprehensive diabetes care and advancing connected solutions for precise diabetes management. Bigfoot Biomedical Inc., a US-based medical technology company, specializes in intelligent insulin administration systems for diabetes management.
Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.
North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-injectable insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-injectable insulin market consists of sales of oral insulin, inhaled insulin, nasal insulin, carrier agents, and stabilizers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-injectable Insulin Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses non-injectable insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-injectable insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-injectable insulin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Insulin Type: Oral Insulin; Inhaled Insulin; Nasal Insulin; Buccal Or Sublingual Insulin; Transdermal Insulin
2) By Product: Pills; Sprays; Other Products
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Drug Stores
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.5 Formulation Innovations For Improved Bioavailability
5. Non-injectable Insulin Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Diabetes Care Centers
5.4 Pharmacies
5.5 Homecare Patients
6. Non-injectable Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Non-injectable Insulin Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Non-injectable Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Non-injectable Insulin Market Size, Comparisons And Growth Rate Analysis
7.3. Global Non-injectable Insulin Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Non-injectable Insulin Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Non-injectable Insulin Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Non-injectable Insulin Market Segmentation
9.1. Global Non-injectable Insulin Market, Segmentation By Insulin Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.5. Global Non-injectable Insulin Market, Sub-Segmentation Of Inhaled Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems
9.6. Global Non-injectable Insulin Market, Sub-Segmentation Of Nasal Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin
9.7. Global Non-injectable Insulin Market, Sub-Segmentation Of Buccal Or Sublingual Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Non-injectable Insulin Market, Sub-Segmentation Of Transdermal Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Non-injectable Insulin Market
12.1. China Non-injectable Insulin Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Non-injectable Insulin Market
13.1. India Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Non-injectable Insulin Market
14.1. Japan Non-injectable Insulin Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Non-injectable Insulin Market
15.1. Australia Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Non-injectable Insulin Market
16.1. Indonesia Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Non-injectable Insulin Market
17.1. South Korea Non-injectable Insulin Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Non-injectable Insulin Market
19.1. South East Asia Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Non-injectable Insulin Market
20.1. Western Europe Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Non-injectable Insulin Market
21.1. UK Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Non-injectable Insulin Market
22.1. Germany Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Non-injectable Insulin Market
23.1. France Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Non-injectable Insulin Market
24.1. Italy Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Non-injectable Insulin Market
25.1. Spain Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Non-injectable Insulin Market
26.1. Eastern Europe Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Non-injectable Insulin Market
27.1. Russia Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Non-injectable Insulin Market
28.1. North America Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Non-injectable Insulin Market
29.1. USA Non-injectable Insulin Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Non-injectable Insulin Market
31.1. South America Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Non-injectable Insulin Market
32.1. Brazil Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Non-injectable Insulin Market
33.1. Middle East Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Non-injectable Insulin Market
34.1. Africa Non-injectable Insulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Non-injectable Insulin Market, Segmentation By Insulin Type, Segmentation By Product, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Non-injectable Insulin Market Regulatory and Investment Landscape
36. Non-injectable Insulin Market Competitive Landscape And Company Profiles
36.1. Non-injectable Insulin Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Non-injectable Insulin Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Non-injectable Insulin Market Company Profiles
36.3.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
37. Non-injectable Insulin Market Other Major And Innovative Companies
